Cross-Sector entity
All 1 tracked stories fall under one category: clinical-trial. The Lancet is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Medicinal Cannabis Industry appears in 1 tracked Cross-Sector story from March 17, 2026. The tracked stories average 2 original sources each.
1 verified story tracked
Last mentioned: Mar 17, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: clinical-trial. The Lancet is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Medicinal Cannabis Industry appears in 1 tracked Cross-Sector story from March 17, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Medicinal Cannabis Industry. Shared-story counts are live from our verified record — not editorial picks.
A comprehensive study published in The Lancet concludes that medicinal cannabis is largely ineffective for treating anxiety, depression, and PTSD. These findings challenge the rapidly growing global market for cannabinoid-based mental health treatments and highlight a significant gap between patient perception and clinical evidence.
